Geron Corporation ( GERN) is a biopharmaceutical company, it develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Geron has substantial insider buying, which could signal deep value. This stock is off by over 55% so far in 2011. The current price is $2.26 with an analyst 1 year price target of $7.33, which could mean 224.34% upside potential. This potential upside is reflected not only in the analysts consensus, but also in insider buying. Geron Corp. has a market cap of $297 million and an enterprise value of $155 million, and has no profit as of yet. The operating cash flow is -$52 million and leveraged free cash flow is -$45 million. On the balance sheet, however, total cash is $152 million and no debt, which shows great potential for managing money. A good reason to look at this stock as a possible buy is the fact that a director just bought 50,000 shares, or $101,500 worth of stock at a price of $2.03 per share.
seekingalpha.com |
